GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
41.01
+0.18 (+0.44%)
At close: 4:02PM EDT

41.01 -0.00 (-0.00%)
After hours: 4:11PM EDT

Stock chart is not supported by your current browser
Previous Close40.83
Open40.94
Bid0.00 x 0
Ask0.00 x 0
Day's Range40.91 - 41.10
52 Week Range37.20 - 44.54
Volume3,415,952
Avg. Volume3,178,720
Market Cap95.07B
Beta0.95
PE Ratio (TTM)40.77
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.99 (4.84%)
Ex-Dividend Date2017-08-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • What to Expect from Big Pharmas After J&J's Solid Q3 Results?
    Zacks8 hours ago

    What to Expect from Big Pharmas After J&J's Solid Q3 Results?

    Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

  • Market Realist16 hours ago

    What GlaxoSmithKline’s 3Q17 Performance Tells Us

    GSK stock fell ~4.7% in 3Q17 but has risen ~6.0% YTD (year-to-date) as of October 16.

  • Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada
    Zacks2 days ago

    Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

    GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.

  • 5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings
    Zacks5 days ago

    5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings

    The pharma/biotech sector has a number of things going in its favor.

  • Reuters5 days ago

    GlaxoSmithKline's shingles vaccine gets approval in Canada

    (Reuters) - Canadian health regulators have approved GlaxoSmithKline's (GSK.L) key shingles vaccine, the company said on Friday. Shingrix, the British pharma company's shingles vaccine for people aged ...

  • CNBC6 days ago

    Pharma companies are starting to recruit top talent from tech giants like Google and LinkedIn

    Pharma companies are recruiting technologists to help speed up their drug discovery and development processes.

  • The Wall Street Journal7 days ago

    [$$] Ebola Vaccines Show Promise in New Study

    The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...

  • May to consult business leaders on Brexit
    Reuters10 days ago

    May to consult business leaders on Brexit

    Prime Minister Theresa May will meet GlaxoSmithKline, Vodafone and HSBC and other major companies on Monday to hear what they want from talks on Britain's relationship with the EU after Brexit. Businesses have become increasingly alarmed by the slow progress of negotiations and the prospect that the country could crash out of the trading bloc without a deal in 2019.

  • 3 High-Yield Healthcare Stocks
    Motley Fool11 days ago

    3 High-Yield Healthcare Stocks

    If you're on the hunt for above-average yields, these three healthcare stocks should be on your radar.

  • Financial Times13 days ago

    [$$] Consumer drugs do not always work for big pharma 

    There is a big difference between a cold and the flu - and it is a distinction on which drugmakers have long relied when selling throat lozenges and fortified lemon drinks over the counter for one condition ...

  • Market Realist14 days ago

    Changes in GlaxoSmithKline’s Valuation

    As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.

  • Market Realist14 days ago

    Performance of GlaxoSmithKline’s Consumer Healthcare Segment

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment has improved its supply chain over the last few years while adding new products to the portfolio.

  • Market Realist14 days ago

    Quarterly Performance of GlaxoSmithKline’s Vaccines Segment

    The Vaccines segment reported a 16.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16.

  • Emergent Completes Acquisition of Anthrax Drug Raxibacumab
    Zacks14 days ago

    Emergent Completes Acquisition of Anthrax Drug Raxibacumab

    Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline.

  • Market Realist15 days ago

    Quarterly Performance for GlaxoSmithKline’s HIV Business

    HIV products reported a 29.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16, driven by the strong performances of Tivicay and Triumeq.

  • Market Realist15 days ago

    GlaxoSmithKline’s Pharmaceuticals Segment in 2Q17

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment reported a 3.0% rise in revenues at constant exchange rates and a 9.0% positive impact of foreign exchange in 2Q17.

  • Market Realist15 days ago

    GlaxoSmithKline’s Quarterly Revenues

    GlaxoSmithKline (GSK) reported a 12.0% rise in revenues to 7.3 billion pounds in 2Q17 compared to 6.5 billion pounds in 2Q16.

  • Market Realist15 days ago

    GlaxoSmithKline’s Recent 3Q17 Developments

    On September 27, 2017, the Japanese Ministry of Health, Labour and Welfare approved Benlysta for the treatment of systemic lupus erythematosus in patients not cured with existing therapies.

  • Reuters16 days ago

    U.S. judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline

    U.S. District Judge Nitza Quinones Alejandro in Philadelphia on Friday threw out the case by British investigator Peter Humphrey and his American wife, Yu Yingzeng, who were arrested in 2013 in China after GSK hired them to look into a former employee. The judge said a U.S. Supreme Court ruling barred lawsuits filed under the federal Racketeer Influenced and Corrupt Organizations Act (RICO) over injuries that occur entirely outside the United States such as this one involving incidents in China.

  • Reuters16 days ago

    U.S. judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline

    U.S. District Judge Nitza Quinones Alejandro in Philadelphia on Friday threw out the case by British investigator Peter Humphrey and his American wife, Yu Yingzeng, who were arrested in 2013 in China after GSK hired them to look into a former employee. The judge said a U.S. Supreme Court ruling barred lawsuits filed under the federal Racketeer Influenced and Corrupt Organizations Act (RICO) over injuries that occur entirely outside the United States such as this one involving incidents in China.

  • Reuters16 days ago

    U.S. judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline

    A U.S. judge has dismissed a lawsuit by two former corporate investigators who accused GlaxoSmithKline Plc (GSK) of misleading them into investigating a whistleblower in China, leading to their arrest amid a bribery scandal involving the drugmaker. U.S. District Judge Nitza Quinones Alejandro in Philadelphia on Friday threw out the case by British investigator Peter Humphrey and his American wife, Yu Yingzeng, who were arrested in 2013 in China after GSK hired them to look into a former employee.

  • Benzinga21 days ago

    Attention Biotech Investors, Here's Your PDUFA Primer For October

    The biotech space can be an investor's delight, fetching staggering returns, while at the same time taking them through the throes of despair if bets go wrong — all courtesy of make-or-break events. In ...

  • Agenus (AGEN) Remains Focused on Drug Development Programs
    Zacks21 days ago

    Agenus (AGEN) Remains Focused on Drug Development Programs

    Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.

  • AstraZeneca's Bevespi Improves Lung Function in Phase III Study
    Zacks22 days ago

    AstraZeneca's Bevespi Improves Lung Function in Phase III Study

    AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.

  • Market Realist22 days ago

    What Happened to Allergan’s Valuation after 2Q17?

    Of the 21 analysts tracking Allergan stock, 14 recommend a “buy,” and seven analysts recommend a “hold.” None recommends a “sell.”